Myomo, Inc. (MYO)

Myomo, Inc.'s stock price has experienced a significant decline over the past year. Key events impacting the stock in the past six months include the release of the Third Quarter and Fourth Quarter 2025 financial results, an agreement with Elevance Health for multi-state network participation, and a price target decrease by Fintel. The stock has shown a recent 5-day and 1-month increase, but a 3-month and 6-month decrease. The 52-week range for the stock has been between $0.60 and $4.99.

Myomo, Inc. has indicated that it expects its "historical seasonal pattern to continue" for the first quarter of 2026. However, specific details regarding the seasonality of demand for Myomo's products are not explicitly available in the provided information.

Myomo, Inc. is a wearable medical robotics company focused on designing, developing, and producing myoelectric orthotics for individuals with neuromuscular disorders. Their primary product, the MyoPro, is a myoelectric-controlled upper limb brace that uses non-invasive sensors to restore arm and hand function. The company also offers MyoPro 2, MyoPro2+, MyoGames, and MyoPro 2x Video Library, along with MyoCare, MyoPal, and MyoCoach. These products are intended for adults and adolescents with neuromuscular conditions resulting from conditions such as brachial plexus injury, stroke, traumatic brain injury, and spinal cord injury.

Myomo, Inc. has a geographic footprint that includes the United States, Germany, and other international markets. The company's corporate office is located in Burlington, Massachusetts. Myomo sells its products through various channels, including orthotics and prosthetics providers, the Veterans Health Administration (VA), and distributors globally. The United States accounts for the majority of its revenue, followed by Germany. The company has also established a joint venture in China to expand its presence in that market. MyoPro is referred to patients at leading rehabilitation facilities across the U.S., including Mayo Clinic, Cleveland Clinic, Massachusetts General Hospital, and twenty VA hospitals.

Myomo's brand reputation is built on its commitment to improving the lives of individuals with upper extremity paralysis by providing effective, safe, and reliable medical products. The MyoPro device is referred to patients at leading rehabilitation facilities, which speaks to its clinical acceptance and perceived efficacy. The company's patented technology, developed at MIT and Harvard Medical School, also contributes to its reputation as an innovator in wearable medical robotics. The agreement with Elevance Health for multi-state network participation in March 2026 could positively impact its reputation and accessibility.

Myomo, Inc. has a diverse ownership structure, with 36.84% held by institutional shareholders, 11.53% by Myomo insiders, and 51.63% by retail investors. Major institutional owners include Rosalind Advisors, Inc., BlackRock, Inc., and Vanguard Group Inc. Key individual and insider owners include Paul R. Gudonis (President, CEO & Chairman), Mgc Venture Partners 2013 LP, Steve Sanghi, and Thomas F. Kirk (Lead Independent Director).